Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study
Authors:
- Robert C. SmithRSRobert C. Smith
- Erin KellyEKErin Kelly
- Thomas F. VivianoTVThomas F. Viviano
- Sumathi VaidhyanathaswamySVSumathi Vaidhyanathaswamy
- 1 July 2010
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 120 (1-3) , 204-209
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly Pharmaceuticals
This publication has 22 references indexed in Scilit:
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidoneSchizophrenia Research, 2009
- Are we ready for a prospective study to investigate the role of chylomicrons in cardiovascular disease?Atherosclerosis Supplements, 2008
- Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in WomenJAMA, 2007
- Methodology for studying postprandial lipid metabolismEuropean Journal of Clinical Nutrition, 2007
- Cross-sectional Comparison of Fasting Lipids in Normoglycemic Patients With Schizophrenia During Chronic Treatment With Olanzapine, Risperidone, or Typical AntipsychoticsJournal of Clinical Psychopharmacology, 2006
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaNew England Journal of Medicine, 2005
- Definition of Metabolic SyndromeCirculation, 2004
- Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart DiseaseArchives of internal medicine (1960), 2003
- Effects of Olanzapine on Lipid Abnormalities in Elderly Psychotic PatientsDrugs & Aging, 2003